Restart Life Sciences CorpCanadian Securities Exchange:HEALView on OTC Pink - Current Information
- LAST PRICE0.0400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0100/ 150
- Ask / Lots0.0400/ 63
- Open / Previous Close0.0400 / 0.0400
- Day Range
- 52 Week Range
- Volume2,804
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HEAL |
|---|---|---|
| 01:33 ET | 2000 | 0.04 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Restart Life Sciences Corp | 1.2M | -1.9x | --- |
MYND Life Sciences Inc | 1.2M | -4.2x | --- |
Zenith Capital Corp | 786.8K | -1.3x | --- |
GeneTether Therapeutics Inc | 775.8K | -1.0x | --- |
Claritas Pharmaceuticals Inc | 974.6K | -0.3x | --- |
Vaxil Bio Ltd | 1.4M | -12.5x | --- |
Company Information
Restart Life Sciences Corp., formerly Nova Mentis Life Science Corp., is a Canadian life sciences company. The Company is engaged in addressing health challenges with and transformative wellness solutions. Its flagship developments include Autism Spectrum, Health-Related Foods, Canada’s First Psilocybin Clinical Trial for Fragile X Syndrome, Orphan Drug Designation (FDA and EMA), and IP Conveyance Agreement with Ludwig Enterprises Inc. (LUDG). It is at the forefront of developing natural remedies specifically tailored for individuals on the autism spectrum. It focusses is on creating health foods that address the needs of this community. It creates high-quality products that promote overall wellness and support healthier lifestyles. It is developing health-related foods that promote both mind and body wellness for healthy living. Its propriety psilocybin drug for the treatment of fragile X syndrome (FXS), the genetic cause of symptoms related to autism spectrum disorder (ASD).
Contact Information
- Headquarters
- 838 West Hasting Street #700VANCOUVER, BC, Canada V6C 0A6
- Phone
- 778-819-0244
- Fax
- 778-819-0244
Executives
- President, Chief Executive Officer
- Steve Loutskou
- Chief Financial Officer
- Rebecca Hudson
- Corporate Administrator
- Kelly Pladson
- Director
- Georg Hochwimmer
- Director
- Derek Ivany
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 29.7M |
Restart Life Sciences Corp does not pay a dividend. | |
Beta | 0.61 |
EPS | $-0.02 |
Book Value | $-0.03 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
